The DOI matches its Crossref record.
Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association.
Abstract
PURPOSE: Pelvic radiation is standard treatment for women with stage IIb to IVa cervical cancer, but treatment results are disappointing, particularly for women with bulky tumors. We investigated the role of primary chemotherapy followed by pelvic radiotherapy in a randomized trial. PATIENTS AND METHODS: Two hundred sixty patients with stage IIb and IVa cervical cancer received either standard pelvic radiotherapy or primary chemotherapy with cisplatin 60 mg/m2 and epirubicin 110 mg/m2 administered at 3-week intervals for three cycles, followed by pelvic radiotherapy. RESULTS: Ninety-nine patients have relapsed with a median follow-up duration of 1.3 years; in 62 patients, the first site of progressive disease was the pelvis. Patients who received primary chemotherapy had a significantly higher pelvic failure rate than those who received radiotherapy alone (P < .003). Seventy-six patients have died, and those who received primary chemotherapy had significantly inferior survival compared with those who received radiotherapy alone (P = .02). Tumor response following chemotherapy was observed in 63%. After radiotherapy, tumor response occurred in 72% of those who received combined modality treatment, compared with 92% of those who received radiotherapy alone. CONCLUSION: Primary chemotherapy with epirubicin and cisplatin, although resulting in tumor response in a significant proportion of patients, is accompanied by an inferior local control rate and survival compared with standard pelvic radiotherapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Eifel, P. J., Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., Rotman, M., Gershenson, D., & Mutch, D. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.197 · Cited by 1,018
Gupta, S., Maheshwari, A., Parab, P., Mahantshetty, U., Hawaldar, R., Sastri (Chopra), S., Kerkar, R., Engineer, R., Tongaonkar, H., Ghosh, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.9985 · Cited by 459
Cannistra, S. A., & Niloff, J. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341606 · Cited by 365
Neoadjuvant chemotherapy for locally advanced cervical cancer
(2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00425-8 · Cited by 291
Logsdon, M. D., & Eifel, P. J. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00482-9 · Cited by 289
Metadata
- Authors
- Tattersall, M. H., Lorvidhaya, V, Vootiprux, V, Cheirsilpa, A., Wong, F., Azhar, T., Lee, H. P., Kang, S. B., Manalo, A., & Yen, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 1995-02
- Volume
- 13
- Issue
- 2
- Pages
- 444-451
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2263001779
- Cited by
- 183
- References
- 0
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. https://app.cochat.ai/papers/10.1200/jco.1995.13.2.444
- The paper
- Tattersall, M. H., Lorvidhaya, V, Vootiprux, V, Cheirsilpa, A., Wong, F., Azhar, T., Lee, H. P., Kang, S. B., Manalo, A., & Yen, M. S. (1995). Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1995.13.2.444
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.